27.04.2007 – 08:51

Intercell AG

euro adhoc: Intercell AG
Annual Reports
Intercell presents 2006 Annual Report

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.

annual report

27.04.2007

Following a successful year, Intercell AG (VSE, "ICLL") today 
presents its Annual Report 2006.

The illustrated Annual Report contains the audited consolidated 
financial statements according to IFRS and gives detailed information
on Intercell’s latest achievements and anticipated milestones. It 
highlights the company’s progress in product development and the 
scientific and commercial potential of its technology platforms. At 
the same time, Intercell AG publishes its statutory financial report 
according to Austrian GAAP.

The online version of the Annual Report is now available for download
at www.intercell.com. A hard copy can be requested at Intercell’s 
Communication Department by mail(communications@intercell.com) or by 
phone (+43-1-20620-0).

About Intercell AG:

Intercell AG is a growing biotechnology company which focuses on the 
design and Intercell AG is a growing biotechnology company which 
focuses on the design and development of novel vaccines for the 
prevention and treatment of infectious diseases with substantial 
unmet medical need. The Company develops antigens and adjuvants which
are derived from its proprietary technology platforms, and has 
in-house GMP manufacturing capability. Based on these technologies, 
Intercell has strategic partnerships with a number of global 
pharmaceutical companies, including Novartis, Merck&Co., Wyeth, 
sanofi pasteur, Kirin and the Statens Serum Institut. The Company’s 
leading product, a prophylactic vaccine against Japanese 
Encephalitis, successfully concluded pivotal Phase III clinical 
trials in 2006. The regulatory process towards a Biologics License 
Application (BLA) to the U.S. Food and Drug Administration (FDA) has 
been initiated. The broad development pipeline includes a Pseudomonas
vaccine in Phase II, a therapeutic vaccine for Hepatitis C in Phase 
II, partnered vaccines for Tuberculosis and S.aureus which are in 
Phase I, and five products focused on infectious diseases in 
preclinical development. Intercell is listed on the Vienna stock 
exchange under the symbol "ICLL".

For more information please visit: www.intercell.com

end of announcement                               euro adhoc 27.04.2007 08:13:24

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market